凯杰生物

Qiagen named Jonathan Pratt as its new CEO effective Sept. 1, succeeding Thierry Bernard, whose exit was already planned for the second half. Shares fell 5% on the Aug. 24 news.

Why it matters: The CEO switch comes amid buyout interest from EQT and KKR and could be interpreted in multiple ways. Pratt led Filtration Group through its sale to Parker Hannifin; this could be seen as valuable experience that may signal the board is leaning toward a sale. The Sept. 1 change could also set a deadline for potential buyers, which could mean a deal may not arrive. Bloomberg reported on July 9 that Qiagen was in talks with EQT and KKR, with a potential offer of at least $50 per share. Shares subsequently rose from $38 to $45 as the market priced in an increasing likelihood of a deal. After the new CEO announcement, shares dropped 5%, indicating growing market skepticism. Pratt brings deep life sciences experience from his time at Waters, Beckman Coulter, and Pall. He was chief executive of Filtration Group until its August sale to Parker Hannifin closed.

The bottom line: Our $49.50/EUR 42 fair value estimate for narrow-moat Qiagen is unchanged by the takeover rumors. Shares screen as undervalued. Qiagen will continue its strategic review, weighing capital allocation across growth pillars or considering a potential sale or merger. Qiagen reiterated full-year guidance of 1%-2% constant-currency sales growth, matching our 1.5% forecast. We see management's targets of 6% midterm growth and adjusted EBIT margin above 31% by 2028 (versus 29.5% in 2025) as achievable, driven by new product launches.

Our fair value estimate is $49.50 per share. We forecast long-term revenue growth of around 6%, above the broader sample preparation market outlook of roughly 4% annually. This outperformance is supported by new product launches, increasing exposure to high-growth end markets such as digital PCR, next-generation sequencing, and bioinformatics, as well as continued market share gains in syndromic testing and QuantiFeron tests.

2026 will be a pivotal year in assessing Qiagen’s progress toward its 2028 constant-currency sales growth target of 7%. The launch of three new products in the sample preparation segment and further evidence of the QIAstat-Dx platform's scaling potential in molecular diagnostics should provide important proof points. We expect these initiatives to establish a solid foundation for maintainable growth, underpinning our long-term 6% revenue assumption.

Management is on track to achieve its 31% adjusted operating margin target in 2028, having reached 29.5% in 2025. We project margins to expand to 32% over the next five years, driven by operational efficiencies, portfolio streamlining following the discontinuation of the NeuMoDx platform, and an improved mix with greater exposure to higher-growth areas such as digital PCR and genomics. Our projected margin exceeds the precovid level of approximately 27% but remains below the covid-driven peak of 33.5%.

We assign Qiagen a narrow Morningstar Economic Moat Rating based on intangible assets and customer switching costs. We see switching costs arising from a high level of recurring sales on its installed base of closed-loop equipment, with multiyear lock-in periods resulting from instrument rental agreements and recurring reagent sales. We expect Qiagen to generate excess economic profits over the next 10 years, with a return on invested capital of 13.8% in 2029.

Recurring sales account for approximately 85% of Qiagen's total revenue, primarily driven by consumables and reagents. To support this model, Qiagen provides instruments such as QIAstat and QIAcuity either through outright sales or, more commonly, through three- to five-year rental agreements that include minimum consumable purchasing commitments. Combined with the training and workflow integration required once a platform is adopted, this produces predictable revenue and meaningful switching costs.

Sample preparation, which makes up 32.5% of sales, has a narrow moat stemming from intangible assets and switching costs. This segment covers kits and instruments for extracting and preparing DNA, RNA, and protein samples—the critical first step in molecular lab workflows, since its reliability directly affects downstream results. Qiagen offers the broadest portfolio in this area, with more than 350 preparation kits and a wide range of instruments spanning low- to high-throughput systems. Key platforms include QIAsymphony, a fully automated, high-throughput system for laboratories seeking platform flexibility, and QIAcube, which provides cost-effective automated preparation of up to 12 samples per run for smaller-scale settings. Both serve research and clinical customers. Qiagen has established an installed base of over 28,000 sample preparation instruments. These closed-loop systems drive recurring reagent sales and create meaningful switching costs, as customers—particularly academic and research labs that depend on reproducible results—face both consumable lock-in and the disruption of revalidating workflows on a new platform. Qiagen ranks second globally in sample preparation (10% share, behind Thermo Fisher) and is tied with Thermo Fisher in nucleic acid purification at 16%.

The PCR segment, which accounts for 15.2% of sales, has a narrow economic moat stemming from intangible assets and switching costs. PCR is a core technique for amplifying DNA, RNA, and proteins. The market is fragmented, with Qiagen positioned as a specialty-testing niche player and a leader in digital PCR.

Qiagen's flagship platform, QIAcuity, is a fully automated system that runs both quantitative and digital PCR, with an installed base of more than 40,000 instruments. This places Qiagen among the top three in the overall PCR market, with a 6% share behind Thermo Fisher and Bio-Rad, and a leading 18% share in digital PCR—with the same closed-loop model driving recurring consumable revenue.

Qiagen is recognized as a pioneer in digital PCR, a high-precision niche that enables detection and quantification of extremely small amounts of DNA or RNA with significantly greater sensitivity than traditional PCR. QIAcuity further differentiates itself by processing samples roughly twice as fast as droplet-based systems.

Qiagen's genomics segment (around 12% of sales) provides bioinformatics software and companion diagnostics for therapy selection. Over two decades, Qiagen has built a curated genomic database used across research and clinical applications to accelerate drug discovery and support clinical decisions. According to Qiagen, its curated tool is 125% more accurate than AI-only alternatives, and replicating two decades of scientist-curated data would require significant time and investment. The software is platform- and assay-agnostic, and scientists are reluctant to switch given the convenience and reproducibility advantages, creating both intangible assets and switching costs. Qiagen holds just under a 20% share in the bioinformatics market.

The diagnostic solutions segment, accounting for 38% of sales, is considered a no-moat segment. Qiagen has been a major player in tuberculosis testing since the early 2000s with QuantiFeron, a blood-based test that holds a 70% share of blood-based testing and is gradually taking share from traditional skin-based tests. QuantiFeron is run on testing equipment from a third-party vendor, Diasorin, with which Qiagen has a partnership. This contributes to our no-moat rating on the tuberculosis business, as there is no control over the installed system, making it easy for clients to switch to a cheaper or better test.

QuantiFeron accounts for about 23% of sales, posing concentration risk since regulators can quickly change screening requirements. Qiagen's sales in the US HPV market collapsed from roughly 10% of revenue in 2013 to negligible after screening rules changed, and new competitors entered—a precedent that informs our caution on QuantiFeron.

Qiagen competes in syndromic molecular testing (about 5% of sales) alongside BioMérieux, Diasorin, Roche, and Becton Dickinson. While we assign BioMérieux a narrow moat here, Qiagen's smaller installed base—roughly 4,500 QIAstat-Dx units versus over 26,000 for BioMérieux's Biofire—doesn't warrant one. Qiagen is executing well, with expanded panel coverage, double-digit annual placement growth, and differentiating features such as quantitative CT values and scalable throughput. Still, we expect the market to commoditize over the long term, leaving little durable differentiation.

Qiagen holds over 2,000 patents (with over 300 pending), though we credit only a few years of effective protection given how readily medtech competitors design around them. To stay ahead, Qiagen invests roughly 10% of sales in R&D and has a strong track record of product innovation, which we expect to continue.

Qiagen is active in multiple potentially fast-growing end markets like dPCR and bioinformatics and has product launches coming up, supporting strong growth over the long run.

Qiagen expanded its installed base significantly during the covid-19 pandemic, which should support higher recurring revenue from consumables and reagents in the coming years.

Over the past few years, Qiagen has improved its operational and cost efficiency and is currently ahead of its targets, suggesting that it may realize stronger-than-expected efficiency gains.

Qiagen will continue to face intense competition in its heavily invested diagnostics markets, which could harm financial returns.

Qiagen faces significant concentration risk with its QuantiFeron product. The company could encounter a similar outcome to its HPV test, where sales declined sharply following policy changes.

We see potential technological disruption risk across several of Qiagen’s end markets—including genomics, diagnostics, and digital PCR—where better-capitalized competitors may hold an advantage.